德谷门冬双胰岛素治疗老年超重2型糖尿病患者的效果研究

Effect of Insulin Degludec/Insulin Aspart in Elderly Patients with Overweight Type 2 Diabetes Mellitus

目的:探讨德谷门冬双胰岛素治疗老年超重2型糖尿病(T2DM)患者的效果。方法:选取2021年1月-7月厦门市儿童医院联合福建省协和医院诊治的老年超重T2DM患者66例作为研究对象,根据治疗方法把患者分为研究组与对照组,各33例。对照组给予门冬胰岛素30治疗,研究组给予德谷门冬双胰岛素治疗,比较两组血糖达标时间、胰岛素用量、血糖变化(空腹血糖与餐后2h血糖)、低血糖发生情况及血清指标(PAI-1、APN含量)。结果:研究组胰岛素用量低于对照组(P<0.05);而两组血糖达标时间比较,差异无统计学意义(P>0.05);两组治疗后空腹血糖与餐后2h血糖低于治疗前,且研究组低于对照组(P<0.05);研究组治疗期间低血糖发生率为0.0%,低于对照组的6.1%,但差异无统计学意义(P>0.05);两组治疗后血清PAI-1、APN含量低于治疗前,且研究组低于对照组(P<0.05)。结论:德谷门冬双胰岛素可降低老年超重T2DM患者血糖浓度,减少胰岛素用量,抑制血清PAI-1、APN的释放,且低血糖发生概率较小,安全可靠。

Objective:To investigate the effect of insulin degludec/insulin aspart in the treatment of elderly patients with overweight type 2 diabetes mellitus(T2DM).Methods:A total of 66 elderly patients with overweight T2DM diagnosed and treated in Xiamen Children’s Hospital and Fujian Provincial Harmony Hospital from January 2021 to July 2021 were selected as the research objects.According to the treatment methods,the patients were divided into study group and control group,with 33 cases in each group.The control group was treated with insulin aspart 30,and the study group was treated with insulin degludec/insulin aspart.The time of blood glucose reaching the standard,the dosage of insulin,the changes of blood glucose(fasting blood glucose and postprandial 2 h blood glucose),the occurrence of hypoglycemia and serum indexes(PAI-1,APN content)were compared between the two groups.Results:The insulin dosage in the study group were lower than that in the control group(P<0.05),and there were no statistically significant difference in the time to reach the target blood glucose compared between the two groups(P>0.05).The fasting blood glucose after treatment and 2h postprandial blood glucose in the two groups were lower than before treatment(P<0.05),and the study group were lower than the control group(P<0.05).The incidence of hypoglycemia during treatment in the study group were 0.0%,which were lower than 6.1%in the control group,the difference was not statistically significant(P>0.05).The serum PAI-1 and APN levels after treatment in the two groups were lower than before treatment(P<0.05),which were lower in the study group than the control group(P<0.05).Conclusion:Insulin degludec/insulin aspart can reduce the blood glucose concentration of elderly patients with overweight T2DM,reduce the dosage of insulin,and inhibit the release of PAI-1 and APN in serum.Moreover,the incidence of hypoglycemia is small,and it is safe and reliable.